Altasciences, a drug development solutions company, and Certara (NASDAQ: CERT) announced a strategic partnership to accelerate early-phase drug development programs. The collaboration integrates Certara's biosimulation technology with Altasciences' development platform.

The partnership addresses industry challenges where fewer than half of preclinical drug candidates reach first-in-human trials. According to the companies, failures stem from toxicity, poor pharmacokinetics, lack of efficacy, and difficulties translating animal study results to humans.

The integration combines Altasciences' Acceleration Platform with Certara's strategic drug development services and biosimulation technology. This approach aims to help sponsors establish proof of mechanism earlier, design studies more efficiently, and make go/no-go decisions with greater confidence.

"At Altasciences, we already help sponsors move from first safety assessment to proof of concept with speed and precision," said Marie-Hélène Raigneau, CEO of Altasciences. "By embedding Certara's modeling capabilities into our platform, we can further inform critical decisions earlier and with greater confidence."

The partnership embeds modeling insights and digital workflows into development execution to optimize study designs, refine dosing strategies, and integrate programs across nonclinical, clinical, bioanalytical, and manufacturing services.

"This partnership unlocks new opportunities to improve early development decisions for biotech sponsors and their investors," said Jon Resnick, CEO of Certara. "By embedding modeling and simulation directly into execution, we enable faster, more informed decision-making that ultimately benefits patients."

Altasciences provides integrated drug development solutions including preclinical and clinical study programs, formulation, manufacturing, and analytical services. Certara offers biosimulation software, technology, and services, serving more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.